EP Patent

EP2022778A1 — A crystalline form of (R,R)-tramadol-(S)-naproxene salt

Assigned to Esteve Pharmaceuticals SA · Expires 2009-02-11 · 17y expired

What this patent protects

The present invention concerns a (R,R)-tramadol-(S)-naproxene salt, a crystalline form of (R,R)-tramadol-(S)-naproxene salt, as well as their process for preparation and their uses as medicaments, more particularly for the treatment of pain.

USPTO Abstract

The present invention concerns a (R,R)-tramadol-(S)-naproxene salt, a crystalline form of (R,R)-tramadol-(S)-naproxene salt, as well as their process for preparation and their uses as medicaments, more particularly for the treatment of pain.

Drugs covered by this patent

Patent Metadata

Patent number
EP2022778A1
Jurisdiction
EP
Classification
—
Expires
2009-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Esteve Pharmaceuticals SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.